The usage of GNX in children/adolescents has been recently approved for cyclin-dependent kinase-like 5 (CDKL5) deficiency (39), a disease characterized by epilepsy and intellectual and motor disabilities. Here, CDKL5 is linked to hyperinsulinemic hypoglycemia, familial, 4.